메뉴 건너뛰기
Journal of Infectious Diseases
Volumn 176, Issue 2, 1997, Pages 384-397
Genetic and Immunologic characterization of viruses infecting MN- rgp120-vaccinated volunteers
Author keywords

[No Author keywords available]
Indexed keywords

ARTICLE; CROSS REACTION; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; MONONUCLEAR CELL; PRIORITY JOURNAL; PROVIRUS; VACCINATION; VIRUS ACTIVATION; VIRUS CHARACTERIZATION; VIRUS INFECTION; VIRUS NEUTRALIZATION;
EID: 0030877108     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/514055     Document Type: Article
Times cited : (71)
References (5)
  • 1
    • 0028024901 scopus 로고
    • Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1
    • Belshe RB, Graham BS, Keefer MC, et al. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. JAMA 1994;272:475-80.
    • (1994) JAMA , vol.272 , pp. 475-480
    • Belshe, R.B.1    Graham, B.S.2    Keefer, M.C.3
  • 2
    • 0030586434 scopus 로고    scopus 로고
    • Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120
    • Graham BS, Keefer MC, McElrath MJ, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. Ann Intern Med 1996;125:270-9.
    • (1996) Ann Intern Med , vol.125 , pp. 270-279
    • Graham, B.S.1    Keefer, M.C.2    McElrath, M.J.3
  • 3
    • 16944364380 scopus 로고    scopus 로고
    • Longitudinal vaccine-induced immunity and risk behavior of study participants in AVEG phase II protocol 201
    • Bethesda, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH
    • McElrath MJ, Montefiori DJ, Clements ML, et al. Longitudinal vaccine-induced immunity and risk behavior of study participants in AVEG phase II protocol 201. In: Abstracts from the Eighth Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS. Bethesda, MD: Division of AIDS, National Institute of Allergy and Infectious Diseases, NIH, 1996:216.
    • (1996) Abstracts from the Eighth Annual Meeting of the National Cooperative Vaccine Development Groups for AIDS , pp. 216
    • McElrath, M.J.1    Montefiori, D.J.2    Clements, M.L.3
  • 4
    • 0029565130 scopus 로고
    • Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a synthetic peptide in HIV-negative volunteers
    • Salmon-Ceron D, Excler JL, Sicard D, et al. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 1995;11:1479-86.
    • (1995) AIDS Res Hum Retroviruses , vol.11 , pp. 1479-1486
    • Salmon-Ceron, D.1    Excler, J.L.2    Sicard, D.3
  • 5
    • 0026647845 scopus 로고
    • Neutralization of multiple laboratory and clinical isolates of HIV-1 by antisera raised against gp120 from the MN isolate of HIV-1
    • Herman PW, Matthews TJ, Riddle L, et al. Neutralization of multiple laboratory and clinical isolates of HIV-1 by antisera raised against gp120 from the MN isolate of HIV-1. J Virol 1992;7:4464-9.
    • (1992) J Virol , vol.7 , pp. 4464-4469
    • Herman, P.W.1    Matthews, T.J.2    Riddle, L.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.